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Introduction 
  Researchers have performed studies over the past thirty years trying to show the links 
between human papillomavirus (HPV) infection and cervical cancer (zur Hausen, 2002).   
Investigations began between the years 1974 and 1976 and during the early 1980’s the first HPV 
types, HPV 16 and HPV 18, were found to be present in cervical cancer biopsy samples (zur 
Hausen, 1977). The laboratory of Meisels and Fortin (1976) subsequently published two articles 
highlighting the existence of koilocytes in cervical cancer samples that designated the presence 
of HPV infection.  Koilocytes are altered cervical cells generated by an infection with HPV.  
These cells acquire an “owl-eye” shape caused by shrinking of the nucleus and a “translucent 
halo” that encircles the nucleus. These changes in cellular morphology were the beginning of 
dysplasia that caused cervical malignancies (Meisels & Fortin, 1976). 
  There have also been advances since the 1980’s in the methodology researchers have 
used to prove the causal relationship between HPV infection and cervical cancer.  
Epidemiological studies are imperative to form a relationship between the risk factors for 
development of cervical pathology and cervical cancer.  Originally comparisons were made 
between patients with cervical cancer and control groups based on questionnaires (Bosch, 
Lorincz, Munoz, Meijer & Shah, 2002).  Now with the availability of HPV DNA detection 
technology, it is possible to establish scientifically sound comparisons between high-risk patients 
and control groups.  With this advancement, HPV DNA has been detected in 90-100% of 
cervical cancer cases compared with only 5-20% of cervical samples taken from women in 
control studies (Bosch, Lorincz, Munoz, Meijer & Shah, 2002).  By being able to prove the 
involvement of HPV in the development of cervical cancer, this cancer has become one of the 2 
only human cancers with a direct causal relationship to a particular infection (Bosch, Lorincz, 
Munoz, Meijer & Shah, 2002). 
HPV infection and its possible sequelae have been an area of great interest in the medical 
community due to the unique nature of the relationship of the virus and the pathologies it causes.  
Cancers of the anogenital region and genital warts have been proven to have a very strong causal 
relationship with infection by various types of HPV (Harper, Franco,  Wheeler, Moscicki, 
Romonowski, & Roteli-Martins et al., 2006).  As a result, prevention and screening have been in 
the forefront of management for HPV-related illnesses. By establishing this link between HPV 
infection and cervical cancer, there has been motivation to create a prophylactic vaccine against 
the most common forms of the virus associated with the development of cervical cancer; HPV 16 
and HPV 18 (Harper et al., 2006).  Vaccinations against HPV infection have been developed and 
on the market since 2006 (J. Dillner, Arbyn & L. Dillner, 2007).   
Problem statement 
 
  Infection with HPV has been proven to have a causal relationship with cervical cancer 
and other anogenital pathologies.  A quadrivalent vaccine has been developed in recent years 
with aims to prevent infection and disease caused by four common HPV types.  Even though 
efficacy and immune memory has been shown through five years of vaccine implementation, 
additional studies are needed to explore long-term effects of the vaccine. 
Purpose 
 
  The purpose of this study is to evaluate the current studies of efficacy and 
immunogenicity of the quadrivalent HPV vaccine.  In addition, it is also imperative to focus on 
the long-term effectiveness of the vaccine in order to determine antibody immune response and 
the possible need for booster vaccinations.  3 
Scope 
 
  Articles from peer-reviewed journals will be used to discuss the topic of HPV infection, 
cervical cancer, and the quadrivalent HPV vaccine.  Articles were chosen that have been written 
since the year 1975 to the present.  The scope of research consisted of the pathology of HPV 
infection and corresponding sequelae, physiology of the HPV vaccination, current 
recommendations for the administration of the HPV vaccine. 
Design 
 
  The design of this study is a comprehensive literature review.  It incorporates studies and 
research performed regarding HPV infection, cervical cancer, and the quadrivalent HPV vaccine. 
Literature review 
 
  It has been shown that 30-50% of the population of the United States has tested positive 
for HPV in the anogenital area (Brinkman, Hughes, Stone, Caffrey, Muderspach, & Roman et 
al., 2007).  This ranks HPV near the top for the most common sexually transmitted infections 
(Brinkman et al., 2007).  In a study by Walboomers, Jacobs, Manos, Bosch, Kummer, & Shah et 
al. (1999), it was shown that 99.7% of all cervical carcinomas were found to be linked to HPV.  
This proved that cervical cancer, which is the cancer ranked second worldwide for causing the 
highest mortality in women, is vastly associated with infection by HPV (Brinkman et al., 2007).  
On a global scale, about 510,000 incident cases and 288,000 deaths from cervical cancer are 
reported every year (World Health Organization, 2004).  In the United States cervical cancer is 
the tenth most common cancer-related cause of death in women with approximately 13,000 new 
cases and 4,500 deaths annually (Saslow, Runowicz, Solomon, Moscicki, Smith, & Eyre, 2004).  
Along with cervical cancer, human papillomaviruses are also known to cause associated pre-
cancerous lesions and genital warts (Francheschi, 2005). 4 
  Multiple risk factors have been identified in regards to HPV infection and cervical 
cancer.  Younger age of first sexual intercourse and increased number of sexual partners are two 
risk factors reported in numerous studies (Basemen & Koutsky, 2005).  There also exists 
considerable socioeconomic, racial, and ethnic disparities associated with incidence, mortality, 
and survival connected with cervical cancer in the United States (Singh, Miller, Hankey & 
Edwards, 2004). 
  By establishing the relationship between HPV and cervical cancer, a vaccination has been 
developed as prophylaxis and protection against the most common types of the HPV.  The 
company Merck Sharp and Dohme developed a quadrivalent vaccine containing HPV types 6, 
11, 16, and 18.  It was approved by the United States Food and Drug Administration on June 8, 
2006 for use in females between the ages of nine and twenty-six years of age (J. Dillner, Arbyn 
& L. Dillner, 2007).  The accepted indications of the vaccine include protection against genital 
warts, cervical cancer, cervical adenocarcinoma in situ, cervical intraepithelial neoplasia grades 
I, II, and III, vulvar intraepithelial neoplasia grades II and III, and vaginal intraepithelial 
neoplasia grades II and III caused by the four types of HPV in the vaccine (J. Dillner, Arbyn & 
L. Dillner, 2007). 
  In addition to the prophylactic vaccination, screening for precancerous lesions has been 
shown to decrease the burden of cervical cancer in the United States (Basemen & Koutsky, 
2005).  The HPV vaccine is aimed at protection for individuals who have not been exposed to the 
virus and only protects against four specific types.  For this reason, routine screening by the 
cytologic Papanicicoloau smear is still a necessary medical intervention (J. Dillner, Arbyn & L. 
Dillner, 2007). 
Research question/hypothesis 
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  Are the current interventions and prevention strategies aimed at lowering the incidence 
and prevalence of HPV infection and cervical cancer effectively decreasing the number of 
women in the United States contracting these diseases?  Is it necessary to further develop a 
public health initiative and education program designed to decrease the burden of HPV infection 
and cervical cancer in women throughout the United States? 
Definitions 
 
Human papillomavirus (HPV): A DNA virus that is transmitted by skin-to-skin contact.  Some 
HPV types cause warts, while others may cause cancerous and precancerous lesions.  
Over 40 types of HPV have been identified (Bosch, Lorincz, Munoz, Meijer, & Shah, 
2002). 
Vaccination: The administration of antigenic material to produce immunity to a disease (J. 
Dillner, Arbyn, & L. Dillner, 2007). 
Cervix:  The lower, narrow portion of the uterus where it joins with the top end of the vagina 
(Ho, Bierman, Beardsley, Chang, & Burk, 1998). 
Methodology 
 
  Articles were found through the use of PubMed and Medline databases.  Search terms 
included human papillomavirus/HPV, HPV vaccine, and cervical cancer. 
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Literature Review 
Human papillomavirus and sequelae 
Pathogenesis of HPV infection 
  It has been shown that an individual’s immune system plays an important role in 
controlling HPV infections (zur Hausen, 2002).  This conclusion has been inferred indirectly 
from showing that there is extended persistence and increased incidence of squamous 
intraepithelial lesions in women who are immunosuppressed (Petry, Scheffel, Bode, Gabrysiak, 
Kochel, & Kupsch et al., 1994).  Studies have also shown that there is the presence of helper T 
cells in cervical lesions that are regressing and involvement of a humoral immune reaction 
against HPV antigens (Jenson, Kurman & Lancaster, 2000).  Chardonnet, Viac, Staquet, and 
Thivolet (1985) were able to demonstrate the presence of helper T cells by investigating the 
cellular immune response in cervical lesions and anogenital warts.  They used monoclonal 
antibodies for helper T cells, circulating T cells, and cytotoxic T cells on 60 samples of HPV-
infected tissue and found T cells to be present in all specimens (Chardonnet, Viac, Staquet & 
Thivolet, 1985).  Furthermore, they also showed the incidence of lesions caused by HPV 
increased in patients who were currently on immunosuppressive therapy or had malignant 
immunological diseases, such as chronic lymphatic leukemia (Chardonnet, Viac, Staquet & 
Thivolet, 1985).  The ability of the HPV infection to progress to dysplasia has been closely 
linked to the capability of the virus to escape from normal physiological immune system 
regulation (zur Hausen, 2002). 
  The acknowledged pathway in cervical carcinogenesis begins with infection by an 
oncogenic type of HPV, progression to a high-grade squamous intraepithelial lesion, 
advancement to carcinoma in situ, and finally a fully invasive form of cervical cancer (Basemen 7 
& Koutsky, 2004).  Low-grade squamous intraepithelial lesions are a temporary viral infection 
and occur when the epithelial cells infected with HPV differentiate and mature but only exhibit 
slight cellular irregularities (Basemen & Koutsky, 2004).  High-grade squamous intraepithelial 
lesions, which are the precursors to cervical cancer, occur through infection of immature basal 
epithelial cells; therefore causing the cells to replicate while not fully developed and genetic 
abnormalities accumulate, ultimately leading to the cloning of cancerous cells (Basemen & 
Koutsky, 2004).  Low-grade squamous intraepithelial lesions are most often found in locations 
more distal from the cervical os, whereas high-grade squamous intraepithelial lesions are 
frequently located more proximally (Basemen & Koutsky, 2004). 
  Human papillomaviruses are nonenveloped icosahedral-shaped capsids with a 55 
millimeter diameter that surround a double-stranded genome of DNA that is around eight 
thousand base pairs long (Munger, Baldwin, Edwards, Hayakawa, Nguyen, & Owens et al., 
2004).  Human papillomaviruses are unable to encode for proteins to make their own enzymes 
and are critically dependent on using the host cell’s cellular machinery for proliferation (Munger 
et al., 2004).  An important step in the life cycle of the human papillomavirus is the necessity for 
the virus to use basal mucosal or epidermal epithelial cells in order to replicate (zur Hausen, 
2002).  Once initial viral infection occurs, three specific oncogenes are produced and cause much 
of the dysplastic cellular growth: oncogenes E5, E6, and E7 (zur Hausen, 2002).  Oncogene E5 is 
responsible for inciting increased cellular growth by forming complexes with three specific 
receptors: colony stimulating factor receptor, platelet derived growth factor  receptor, and the 
epidermal growth factor receptor (zur Hausen, 2002).  Oncogene E5 also plays a role in 
hindrance of cellular apoptosis that should naturally occur once any host cellular DNA damage 
has occurred (zur Hausen, 2002).  Oncogenes E6 and E7 are more closely related to the 8 
malignant processes that HPV infection can cause because they actively obstruct cell cycle 
control mechanisms (Brinkman et al., 2007).  Protein p53 is necessary for repairing any damage 
to DNA and is a mediator in the G1 cell cycle step of suspending cellular growth or apoptosis 
when the cell has incurred considerable DNA damage; the ultimate result is accumulation of 
genetic mutations and cellular instability (Favre, Ramoz & Orth, 1997).  Oncogene E6 has been 
shown to interfere with the normal function of p53 (Werness, Levine & Howley, 1990). The E7 
oncoprotein interacts with the retinoblastoma tumor suppressor protein; the effect is poor 
regulation of the cell cycle and inability to properly direct basal epithelial cell proliferation 
(Brinkman et al., 2007).  The three oncogenic proteins E5, E6, and E7 have been steadily found 
in malignant tissue biopsy samples of cervical cancer (zur Hausen, 2002).  Malignant phenotype 
of cervical cancer cells has been successfully inhibited if the expression of the three genes has 
been blocked (zur Hausen, 2002). 
Background of HPV and cervical cancer 
 
  HPV infection is a very common infection.  Even with this reality, a large percentage of 
infected people clear the virus before it causes clinically significant pathologies (Basemen & 
Koutsky, 2005).  For those women who cannot clear the viral infection simply through their 
immune processes, multiple possible medical sequelae can result.  More than forty types of HPV 
have been detected and are known to infect the human anogenital region (zur Hausen, 1996).  
The various HPV types have been classified according to their severity of risk associated with 
advancement to cervical cancer: fifteen are categorized as high-risk for development of cervical 
cancer, three are probable high-risk, twelve are considered low risk, and three are classified as 
undetermined risk (Munoz, Bosch, de Sanjose, Herrero, Castellsague, & Shah et al., 2003).  
Those included in the high risk human papillomavirus category include HPV 16, 18, 31, 33, 35, 9 
39,45, 51, 52, 56, 58, 59, 68, 73, and 82; probable high-risk types include HPV 26, 53, and 66; 
low risk HPV types are 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108; and the HPV types 
considered undetermined risk are 34, 57, and 83 (Munoz et al., 2003).   
  Globally, the second most common cancer in women is cervical cancer (Ries, Eisner, 
Kosary, Hankey, Miller, & Clegg et al., 2004) and mortality from cervical cancer ranks third 
worldwide (Pecorelli, Favalli, Zigliani, & Odicino, 2003).  Since 2000, there has been an average 
of 470,000 incident cases of cervical cancer across the world every year (Baseman & Koutsky, 
2005).  The average age for diagnosis of cervical cancer is forty-seven years old, which is 
typically ten to twenty years after the HPV infection occurs (Markowitz, Dunne, Saraiya, 
Lawson, Chesson, & Unger et al., 2007).  In addition, 3.5 to 5 million women each year have 
abnormal Papanicolaou smears and necessitate procedures for prevention of progression to 
cervical cancer (Ohri, 2007). 
Annually in the United States there are approximately 6 million new cases of active 
genital HPV infections (Weinstock, Berman & Cates, 2004).  It is estimated that 20 million 
residents of the United States have existing HPV infections; this is approximately 15% of the 
country’s population and just under half of these infections occur in people between the ages of 
fifteen and twenty-five years of age (Koutsky, 1997).  According to Myers, McCrory, Nanda, 
Bastian, and Matchar (2000), over half of sexually active people will become infected with HPV 
throughout their lifetime and 80% of sexually active women are infected by age fifty. 
In a study conducted with patients from Planned Parenthood, it was shown that 
prevalence of infection with high-risk HPV was 27.4% in women with a median age of twenty-
five years of age (Kulasingam, Hughes, Kiviat, Mao, Weiss, & Kuypers et al., 2002).  The study 
was performed between December 1997 and October 2000 in the state of Washington and 4075 10 
Planned Parenthood patients who presented for their annual examination were screened through 
the use of Papanicolaou smears and detection of high-risk HPV DNA through polymerase chain 
reaction (Kulasingam et al., 2002).  The requirements for participation included being between 
18 and 50 years of age, no previous treatment for cervical dysplasia or malignancy, no history of 
hysterectomy, and no history of a chronic immunosuppressive disease (Kulasingam et al., 2002).  
Abnormal Papanicolaou tests were found in 678 of the 4075, or 16.6% of the participants, and 
the polymerase chain reaction detected high-risk HPV DNA in 747 of the 4075 women, which is 
18.3% of participants (Kulasingam et al., 2002).  The most common type of HPV detected by 
polymerase chain reaction was type 16; it was detected in 214 of the 747 women positive for 
HPV DNA, which is 28.7% of this group (Kulasingam et al., 2002).  Two prevalence estimates 
were made, one before 2000 and one after the year 2000, and the weighted estimate of these two 
together was 27.4% (Kulasingam et al., 2002).  Also, prevalence was found to be similar 
amongst female college students (Richardson et al., 2003).  Richardson, Kelsall, Tellier, Voyer, 
Abrahamowicz, and Ferenczy et al. (2003) had 635 women in their study that was performed 
between 1996 and 1999 at McGill University in Montreal.  These women had an average age of 
23 years old and 45% of them reported they have had five or more sexual partners in their 
lifetime (Richardson et al., 2003).  The women were given an initial screening for HPV infection 
through DNA polymerase chain reaction of cervical cell samples and had serial screening every 
six months for two years.  At the conclusion of the study, the prevalence of HPV infection was 
29.0% for all the participants (Richardson et al., 2003). 
Woodman, Collins, Winter, Bailey, Ellis and Prior et al. (2001) conducted a study that 
showed that over a three-year period the incidence of infection with HPV in women was 44%. 
The study by Woodman et al. (2001) was done between the years of 1988 and 1992 and enrolled 11 
2011 sexually active young women between the ages of 15 and 19 years old.  Of this group, 1075 
were found to be negative for HPV infection and have no cervical cytological abnormalities at 
enrollment in the study (Woodman et al., 2001).  Cervical Papanicolaou smears were given to 
each participant at six-month intervals for continued surveillance (Woodman et al., 2001).  After 
three years 44% (95% CI 40-48) were infected with a type of HPV that was not detected at the 
initiation of the study (Woodman et al., 2001).  A comparable outcome was found in another 
study by Ho, Bierman, Beardsley, Chang and Burk (1998) with 608 female college students in 
New Jersey.  These women were followed at six-month intervals for three years.  At each visit 
cervical cytological samples were obtained for DNA polymerase chain reaction studies and 
hybridization with Southern blot technique.  Papanicolaou smears were also performed annually.  
At the conclusion of 36 months of surveillance, the incidence rate of HPV infection was 43% 
(95% CI 36-49) (Ho, Bierman, Beardsley, Chang & Burk, 1998).   
Diseases caused by HPV  
 
  HPV types 16, 18, 31, 33, and 45 have a causal relationship with malignancies of the 
anogenital region, which includes cervical, vaginal, vulvar, anal, and penile cancers (Koutsky, 
Galloway & Holmes, 1988).  HPV types 16 and 18 are accountable for approximately 70% of 
invasive cervical malignancies (Munoz et al., 2003).  Globally, HPV type 18 is responsible for 
17% of cervical cancer and HPV type 16 causes 54% of cervical malignancies (Munoz et al., 
2003).  Four thousand Americans are diagnosed annually with anal cancer and between fifty and 
sixty percent of these cases are associated with HPV types 16 and 18 (Moscicki, Shiboski, 
Broering, Powell, Clayton, & Jay et al., 2006).  Of these cases of anal cancer, there are a 
resulting 620 deaths each year (Kyrgiou, Tsoumpou, Vrekoussis, Martin-Hirsch, Arbyn, & 
Prendiville et al., 2006).  Cases of vulvar cancer annually total 3,870 with 870 deaths and 40% of 12 
these are related to HPV infection (Wideroff, Schiffman, Haderer, Armstrong, Greer, & Manos 
et al., 1999).    
Human papillomaviruses are the cause of squamous cell cervical cancer and cervical 
adenocarcinoma; the viruses are also the causes of cervical cancer precursor lesions.  The 
precursor lesions include cervical intraepithelial neoplasia grade one or low-grade dysplasia, 
cervical intraepithelial neoplasia grades two and three or moderate to high-grade dysplasia, and 
adenocarcinoma in situ (Miller, Raychaudhuri, & Toerner, 2007).  Human papillomaviruses 
cause 35-50% of vaginal and vulvar cancers.  The papillomaviruses are also responsible for 
vaginal intraepithelial neoplasia grades two and three and vulvar intraepithelial neoplasia grades 
two and three; these kinds of neoplasia are precursor cells to the corresponding cancers (Merck, 
2006).  Saslow, Castle, Cox, Davey, Einstein, and Ferris et al. (2007), along with help from the 
American Cancer Society, reported that 70% of cervical cancers are caused by HPV types 16 and 
18.  
The incidence of high-grade squamous intraepithelial lesions have been shown to be 
associated with oncogenic forms of HPV (Baseman & Koutsky, 2005).  A study by Koutsky, 
Holmes, Critchlow, Stevens, Paavonen, and Beckmann et al. (1992) demonstrates the point that 
high-grade cervical intraepithelial neoplasia is tightly linked to the presence of HPV infection. A 
longitudinal study performed at a clinic in Seattle, Washington randomly enrolled 779 women 
between the ages of 16 and 50 years old that presented with a chief complaint of possible 
sexually transmitted disease (Koutsky et al., 1992).  These women were examined every four 
months by cytological and colposcopic methods and given tests for detection for HPV DNA.  It 
was shown that a group of women who had no previous history of squamous intraepithelial 
lesions also showed a two-year incidence of high-grade cervical intraepithelial neoplasia grade II 13 
or III confirmed by biopsy to be 28% in women who were positive for HPV and 3% in women 
with no detectable HPV infection (Koutsky et al., 1992). HPV types 16 and 18 were found to be 
present in 18% of the women who developed the high-grade cervical intraepithelial neoplasia 
grade II and III and were the types responsible for the largest proportion of the disease. (Koutsky 
et al., 1992).  Similar results were found in another study performed by Woodman, Collins, 
Winter, Bailey, Ellis, and Prior et al. (2001).   The conclusion of Woodman and his colleagues 
showed that women who were negative for both squamous intraepithelial lesions and HPV 
infection at initial enrollment in the experiment and then become infected with HPV were 13 
times more likely to be diagnosed with high-grade squamous intraepithelial lesions than women 
who remained HPV-negative (Woodman et al., 2001) 
More than half a million incident cases of anogenital warts are diagnosed every year in 
the United States and approximately 90% of genital warts are caused by HPV types 6 and 11 (J. 
Dillner, Arbyn & L. Dillner, 2007).  Greer, Wheeler, Ladner, Beutner, Coyne, and Liang et al. 
(1995) studied a group of 39 patients with genital warts.  They found that 94% were positive for 
HPV type 6 (95% CI 82-99) and 8% had lesions positive for HPV type 11 (95% CI 2-22).  Giant 
condylomas are associated with infection by HPV types 6 and 11 and can possibly, although 
uncommon, progress to form malignancies known as Buschke-Lowenstein tumors of the penis, 
vulva, and anus (Cogliano, Baan, Straif, Grosse, Secretan & El Ghissassi, 2005). 
Vaccination against human papillomavirus infection 
 
Formulation of the vaccination 
 
  Now that there has been a proven link between infection with HPV and cervical cancer 
and other genital diseases there is also the potential to prevent these illnesses through 
vaccination.  Research has been conducted recently to formulate an appropriate vaccine for this 14 
purpose.  The vaccine includes the most common HPV types associated with genital diseases, 
HPV types 6, 11, 16, and 18 (J. Dillner, Arbyn, & L. Dillner, 2007).  The discovery of the viral 
etiology of cervical pathology and development of a prophylactic vaccination presents the 
opportunity for universal cervical cancer prevention. 
  The prophylactic vaccination contains virus-like particles (VLPs) and the L1 gene capsid 
protein of the four included types of HPV (Brinkman, Hughes, Stone, Caffrey, Mudersach, & 
Roman et al., 2007).  The HPV L1 VLPs are antigens that resemble the viral capsid and are 
arranged in a specific conformational manner (Brinkman et al).  The HPV L1 VLPs are devoid 
of the viral DNA and therefore the vaccine does not contain live attenuated viruses (Pinto, 
Edwards, Castle, Harro, Lowy, & Schiller, 2003).  Exposing the body’s natural immune response 
to these L1 VLPs causes the production of type-specific antibodies that have the potential to 
combat future infection with the four included types of HPV (Zhou, Sun, Stenzel, & Frazer, 
1991). 
  The quadrivalent HPV vaccine is composed of L1 VLPs of types 6, 11, 16, and 18 (Ault, 
Giuliano, Edwards, Tamms, Kim, Smith, et al., 2004).  The current approved and marketed dose 
contains 20 micrograms of HPV type 6 L1 VLP, 40 micrograms of HPV type 11 L1 VLP, 40 
micrograms of HPV type 16 L1 VLP, and 20 micrograms of HPV type 18 L1 VLP (Olsson, 
Villa, Costa, Petta, Andrade, Malm, et al., 2007).  The multiple HPV types are combined with 
225 micrograms of amorphous aluminum hydroxyphosphate sulfate and make a total injection 
volume dosage of 0.5 milliliters (Olsson et al). 
Initial vaccine studies 
 
  Beginning in 2002 a three-phase trial was performed to assess the efficacy of a 
quadrivalent vaccine aimed at preventing HPV types 6, 11, 16, and 18 (Garland, Hernandez-15 
Avila, Wheeler, Perez, Harper, Leodolter, et al., 2007). The Females United to Unilaterally 
Reduce Endo/Ectocervical Disease (FUTURE I) study was sponsored by the pharmaceutical 
company Merck Sharpe and Dohme to evaluate the vaccine (Garland et al., 2007).  There were 
6463 women between the ages of 16 and 24 screened for eligibility within the first year of the 
study (Garland et al).  Inclusion criteria included women who were not pregnant, had no history 
of genital warts or abnormal Pap smears, and had four or less lifetime sexual partners.  All 
participants were required to use effective contraception during the vaccination period.  A total 
of 5455 women were accepted into the study (84%) and were selected from 62 clinical sites in 16 
different countries.  Through a randomization process 2723 women were included in the group to 
receive the quadrivalent vaccine and 2732 women were assigned to the placebo group.  At the 
onset of the study only 8 women (0.15%) were serologically positive for HPV DNA with all four 
types of HPV covered by the vaccine.  Injections were given at day one, at month two and at 
month six and follow up was continued for three years.  Gynecologic examinations were 
performed at day one and months seven, 12, 24, and 36.  HPV DNA testing and HPV antibody 
testing was performed on cervical, labial, perineal, and perianal swab specimens at day one and 
months three, seven, 12, 18, 24, 30 and 36.  Women were observed for 30 minutes following the 
administration of the vaccine for side effects.  The participants recorded oral temperatures four 
hours after the vaccination and daily for the subsequent four days.  The participating women 
recorded any adverse events for 15 days following vaccination. 
  By the end of the three-year trial just over 83% of the participants were still enrolled in 
the study (Garland, Hernandez-Avila, Wheeler, Perez, Harper, & Leodolter, 2007).  The vaccine 
group contained 2261 subjects and reported zero cases of anogenital pathology.  The placebo 
group had 2279 subjects and reported 60 cases of anogenital pathology.  The quadrivalent HPV 16 
vaccine was shown to be 100% effective (95% CI 94-100) in the prevention of vaginal, vulvar, 
perineal, and perianal intraepithelial lesions and warts associated with HPV types 6, 11, 16 and 
18.  Also 99.5% of subjects in the vaccine group exhibited seroconversion of anti-HPV 
antibodies at month seven, which was one month following the third dose of the vaccine.  The 
overall results of this study showed that anogenital diseases caused by HPV types 6, 11, 16, and 
18, including genital warts and intraepithelial neoplasia of the vulva, vagina, and cervix, are 
preventable through use of a prophylactic quadrivalent HPV vaccination. 
  The safety of the HPV vaccination was also investigated during the preliminary studies.  
There were minor adverse events associated with the administration of the vaccine.  Side effects 
at the site of injection were reported in 83% of the group receiving the vaccine and in 73.4% of 
the placebo group (Villa, Costa, Petta, Andrade, Paavonen, Iversen et al., 2006).  Adverse events 
at the injection site included swelling, erythema, and pain, which all were reported to have 
increased severity in the participants receiving the vaccine (Villa et al).  Systemic complaints 
such as fever, headache, and nausea were reported by 69% of vaccine recipients.  There were no 
deaths during the study period that were a consequence of the vaccination or the procedures 
performed.  Serious adverse events in the vaccine group that occurred during the trials included 
one case of bronchospasm, one case of gastroenteritis, one case of headache accompanied by 
hypertension, one case of joint movement impairment near the injection site, and one case of 
vaginal hemorrhage.  Within the placebo group the serious adverse events reported included one 
case of severe hypersensitivity and one case of fever, chills, and headache.  Adverse events 
caused only 0.2% of participants in both the vaccine and placebo groups combined to 
discontinue the study (Villa et al). 17 
  Prior to application for approval by the Food and Drug Administration, three additional 
randomized double-blind studies were also performed regarding the HPV vaccination (Villa, 
Costa, Petta, Andrade, Paavonen, Iversen et al., 2006).  A Phase II study, known as Protocol 005, 
assessed only the HPV type 16 component of the vaccine.  Another Phase II study, termed 
Protocol 007, evaluated all four types of HPV included in the vaccine.  Finally, another Phase III 
trial in addition to the FUTURE I trial was performed and known as the FUTURE II study.  Both 
of the FUTURE trials tested the form of the quadrivalent vaccine that would eventually be 
approved and marketed under the name Gardasil.  With all four studies combined, 20,541 
women between the ages of 16 and 26 took part in these trials.  In all of the studies, the 
participants were randomly assigned to receive injections of the vaccine or placebo at zero, two 
and six months.  Analysis of efficacy was done individually for each study and for all studies 
combined.  Results of each study and the analysis of efficacy of the quadrivalent HPV vaccine 
are displayed in Table 1 (Villa et al). 
Following the approval and licensing of the quadrivalent HPV vaccine Gardasil, the 
American Cancer Society established a set of recommendations for the use of the vaccine to 
prevent cervical cancer and its precursors (Saslow, Castle, Cox, Davey, Einstein, & Ferris et al., 
2007).  These guidelines state that the routine use of the HPV vaccine it recommended for 
females between the ages of 11 to 12 years old and can be given to females as young as 9 years 
of age.  The HPV vaccine is also suggested to women between the ages of 13 and 18 years old if 
needed to catch up on the vaccine regimen.  The American Cancer Society states that the 
decision to vaccinate women between the ages of 19 and 26 years old should be based on clinical 
discretion regarding the female’s risk of preceding HPV contact and what level of potential 18 
benefit it may afford.  Currently the HPV vaccination is not advised or approved for females 
over 26 years of age or for males. 
Immune memory and prolonged efficacy of the HPV vaccine 
  The basis of using vaccines to prevent the development of particular diseases lies in the 
concept of inducing the body’s own immune system to create an immune memory against an 
offending antigen.  For a vaccine to be effective in providing long-term protection and disease 
prevention it must stimulate the production of memory immune cells that will create a potent 
immune response if there is exposure to antigenic material (Villa, Ault, Giuliano, Costa, Petta, & 
Andrade et al., 2006). 
  A five-year follow-up study was performed and aimed at investigating the prolonged 
efficacy following the administration of the quadrivalent HPV vaccine (Villa, Costa, Petta, 
Andrade, Paavonen & Iversen, 2006).  To date this is the longest study done on the HPV 
vaccination.  This study was arranged in the same way as the Phase II Protocol 007 initial study 
performed.  The focus of the study looked at disease end points in vaccine-receiving groups and 
placebo-receiving groups after five years.  The study included 552 women between the ages of 
16 and 23 years of age to take part in the initial three years of the study.  The HPV vaccine was 
given to 276 participants and the placebo was given to 275 of the women at day zero, month two, 
and month six.  Follow-up was conducted from month seven to month 36 for this cohort of 
women.  Follow-up included Pap testing, anogenital swabbing and analysis, and serum collection 
and analysis.  At the conclusion of the three-year follow-up, 241 women were enrolled in a two-
year extension follow-up study to further investigate prolonged efficacy and immunogenicity.  
Five years after the beginning of the study, the incidence of infection or disease caused by HPV 
types 6, 11, 16, and 18 declined by 96% in the population of women who received the HPV 19 
vaccine as compared to the placebo group.  There were two reported cases of HPV-related 
disease in the vaccine group and 46 cases in the placebo group.  There was also an analysis of 
disease end points base on the specific type of HPV that caused the disease.  For the two cases 
that involved the vaccine group, there was one reported case of infection with HPV 16 and one 
case of infection with HPV 18.  Neither infection proceeded to cause cervical dysplasia.  In the 
placebo group there were 45 women with infection, three that had developed CIN I-III, and three 
with condyloma.  Of these cases, 17 were related to infection with HPV 6, three related to HPV 
11, 28 related to HPV 16, and 11 related to infection with HPV 18.  A complete list presenting 
the results of this study is shown in Table 2.  This study supports the idea that the quadrivalent 
HPV vaccine will sustain long-term efficacy and prevention of anogenital diseases caused by the 
four types of HPV included in the vaccine. 
  Another study that was recently performed focused on the strength of the immune 
memory response upon exposure to the HPV antigens (Olsson, Villa, Costa, Petta, Andrade, & 
Malm et al., 2007).  The study investigated how well the vaccine could produce immune memory 
that was HPV type-specific.  This study began with the same participants that were involved in 
the Protocol 007 study.  After the initial rounds of administration of vaccine or placebo at day 
zero, month two, and month six, 241 women were selected to participate in this specific five-year 
follow up study.  This group of women involved in the extension study received the three 
primary injections of the HPV vaccine, were seronegative for HPV antibodies and PCR-negative 
for HPV DNA at enrollment in the study, and continued to be HPV DNA PCR-negative through 
month 60 of the study.  Levels of type-specific HPV antibodies were recorded at month seven, 
one month following the administration of dose three of the vaccine.  Measurements were 
recorded in geometric mean titers (GMT).  Type-specific antibodies were then also measured at 20 
month 60.  Following the month 60 measurement the subject was re-challenged by the HPV 
antigen by being given another dose of the vaccine.  HPV type-specific antibodies were then 
again measured one week following this administration and at month 61.  This re-challenge with 
HPV antigen produced a considerable immune response as shown by a large increase in the 
GMTs of all four HPV antibody types.  HPV antibody GMTs were highest at month seven 
following the final dose of the vaccine regimen.  Anti-HPV GMTs fell after month seven but 
then reached a stable state by month 24 and stayed at this plateau through the five years of the 
extension study.  Results of GMT studies for each HPV type are shown in Table 3.  This study 
shows that the quadrivalent HPV vaccine has the ability to induce a powerful immune response 
through at least five years following administration.  Even though there is no definition of the 
minimum level of HPV antibodies needed to cause protective efficacy of the vaccine, this study 
gives some evidence that the vaccine will be able to provide long-term protection against HPV-
related diseases. 21 
Conclusion 
 
  Current studies have shown promise for the possibility of eradication and decline in the 
cervical malignancies and other HPV-related pathologies.  It has been estimated that if women 
were given the quadrivalent HPV vaccine before their sexual debut there could be a decrease in 
the risk of anogenital and cervical cancer by at least 85% and a 44-70% decrease in the amount 
of abnormal Pap smears caused by HPV (Walboomers, Jacobs, Manos, Bosch, Kummer, & 
Shah, 1999).  It has also been thought that if the HPV vaccine were available globally it has the 
potential to prevent over 300,000 incident cases annually (zur Hausen, 2002).  Overall, morbidity 
and mortality associated with HPV-related diseases could be dramatically decreased through the 
use of the prophylactic HPV vaccine. 
  Although the current studies through five-year follow-up show great promise for the 
efficacy and immunogenicity of the HPV vaccine, there still remain many questions unanswered.  
Due to the fact that it takes an extended period of time for progression of HPV infection and 
cervical cancer, it will take a considerable amount of time before the actual effects on morbidity 
and mortality will be realized.  It has been suggested that even after vaccination programs are 
effectively executed, it will be at least a decade before a reduction in the incidence of cervical 
cancer will be apparent (Crum, 2002). 
  In the meantime it is important for physician assistants to play an appropriate role in 
helping to implement the HPV vaccine and reduce the incidence of all HPV-related pathologies.  
One of the most important concepts at this time is the continuance of cervical screening 
recommendations.  Even with the promise shown by the HPV vaccine, any hasty reduction of 
routine gynecological examinations and Pap smears could have the potential to cause cervical 
cancer rates to rise.  It is also imperative to educate patients that the HPV vaccine does not 22 
provide protection against all strains of carcinogenic HPV so it is necessary to perform the 
recommended screenings.   
  Overall, the rates of cervical cancer and HPV-related diseases depend on multiple factors 
related to the HPV vaccine.  It will be necessary to continue studies on the long-term efficacy 
and immunogenicity of the HPV vaccine and also determine if there will be a need for booster 
vaccines.  Reduction in HPV-related anogenital pathology also depends on the widespread 
availability of the vaccine to at-risk populations. 
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Table 1 
Efficacy Analysis of Quadrivalent HPV Vaccine 
 
  Quadrivalent HPV vaccine  Placebo  % Efficacy 
(95% CI) 
  n  # of cases  n  # of cases   
 
HPV 16- or 18-related CIN II/III or AIS 
Protocol 005  755  0  750  12  100.0 
(65.1, 100.0) 
Protocol 007  231  0  230  1  100.0 
(-3734.9, 100.0)
FUTURE I  2200  0  2222  19  100.0 
(78.5, 100.0) 
FUTURE II  5301  0  5258  21  100.0 
(80.9, 100.0) 
 
HPV 6-, 11-, 16-, 18-related CIN (CIN I, CIN II/III) or AIS 
 
Protocol 007  235  0  233  3  100.0 
(-137.8, 100.0) 
FUTURE I  2240  0  2258  37  100.0 
(89.5, 100.0) 
FUTURE II  5383  4  5370  43  90.7 
(74.4, 97.6) 
 
HPV 6-, 11-, 16-, 18-related genital warts 
 
Protocol 007  235  0  233  3  100.0 
(-139.5, 100.0) 
FUTURE 1  2261  0  2279  29  100.0 
(86.4, 100.0) 
FUTURE II  5401  1  5387  59  98.3 
(90.2, 100.0) 
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Table 2 
Efficacy of Quadrivalent HPV Vaccine at Five-Year Follow-Up 
 
 Vaccine  Placebo     
End point  n  Cases  n  Cases  Efficacy 
(%) 
95% CI (%) 
Infection or 
disease 
235 2  233  46  95.8  (83.8,  99.5) 
   Infection  235  2  233  45  95.6  (83.3, 99.5) 
  Disease  235  0  233  6  100.0  (12.4, 100.0) 
  CIN I-III  235  0  233  3  100.0  (<0.0, 100.0) 
       Condyloma  235  0  233  3  100.0  (<0.0, 100.0) 
 
End points by 
HPV type 
          
HPV 6  214  0  209  17  100.0  (75.7, 100.0) 
HPV 11  214  0  209  3  100.0  (<0.0, 100.0) 
HPV 16  199  1  198  28  96.6  (79.2, 99.9) 
HPV 18  224  1  224  11  90.6  (35.6, 99.8) 
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Table 3 
Average Geometric Mean Titers Comparing Type-Specific HPV Antibodies From Month Seven 
to Re-challenge at Month 60 
 
  GMT (mMu/mL)  95% CI 
 
HPV 6 
Month 7  549.2  (460.6, 654.7) 
Month 60 (pre-challenge)  67.7  (53.5, 85.7) 
Month 60 + 1 week  503.3  (344.2, 736.1) 
Month 61  693.2  (451.9, 1063.3) 
 
HPV 11 
Month 7  635.5  (521.3, 774.9) 
Month 60 (pre-challenge)  70.1  (52.5, 93.7) 
Month 60 +1 week  1417.5  (1009.0, 1991.4) 
Month 61  2652.4  (1956.7, 3593.3) 
 
HPV 16 
Month 7  3870.0  (3157.0, 4744.0) 
Month 60 (pre-challenge)  404.2  (312.9, 522.1) 
Month 60 + 1 week  4466.4  (3095.2, 6445.0) 
Month 61  5714.0  (3829.7, 8525.4) 
 
HPV 18 
Month 7  741.2  (576.8, 952.4) 
Month 60 (pre-challenge)  44.7  (31.8, 62.8) 
Month 60 + 1 week  1033.2  (753.9, 1415.8) 
Month 61  1230.0  (904.5, 1672.5) 
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Abstract 
 
  Objective: Infection with various types of HPV has a causal relationship with the 
development of cervical cancer and other anogenital diseases.  A prophylactic quadrivalent HPV 
vaccination has been produced.  Here the pathophysiology of HPV infection and results of 
multiple HPV vaccine studies are discussed to determine efficacy and immunogenicity.  
Methods: The review includes articles found through PubMed and MEDLINE that focus on the 
infection with human papillomavirus, cervical cancer, and the HPV vaccine.  Results: An HPV 
vaccine has effectively been produced that has proven to decrease the incidence of cervical 
cancer and other anogenital diseases.  The vaccine has been approved for use in women between 
the ages of 9 and 26 years of age for prevention of anogenital pathology.  Five year follow-up 
studies of the vaccine have shown long-term efficacy and the induction of an immune memory 
response.  Conclusion: Studies to date have shown that the HPV vaccine is effective in reducing 
cervical cancer but it is still too early to know the full extent of vaccine efficacy.  Future studies 
are necessary to continue monitoring the vaccine.  In the meantime it is essential to maintain 
current cervical screening programs and promote patient education.  
 